In an interview with PharmaShots, Dr. Briggs W. Morrison, MD, Chief Executive Officer and Director at Syndax share his views on the license agreement for axatilimab with Incyte to treat cGVHD and other fibrotic diseases
Shots:
The companies collaborated to develop and commercialize Syndax's axatilimab (anti-CSF-1R mAb) & will get a 50:50 US profit share
Incyte will lead the…
